Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford). 2000;39:122–32.

Article  PubMed  CAS  Google Scholar 

Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70:121–45.

Article  PubMed  CAS  Google Scholar 

Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:123–30.

Article  PubMed  Google Scholar 

Kievit W, Fransen J, de Waal Malefijt MC, den Broeder AA, van Riel PLCM. Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. Rheumatology (Oxford). 2013;52:1500–8.

Article  PubMed  Google Scholar 

Greenberg JD, Spruill TM, Shan Y, et al. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med. 2013;126:1089–98.

Article  PubMed  PubMed Central  Google Scholar 

Bruce B, Fries JF, Murtagh KN. Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol. 2007;34:1475–9.

PubMed  Google Scholar 

Helliwell PS, Ibrahim G. Ethnic differences in responses to disease modifying drugs. Rheumatology (Oxford). 2003;42:1197–201.

Article  PubMed  CAS  Google Scholar 

Cullen MR, Lemeshow AR, Russo LJ, Barnes DM, Ababio Y, Habtezion A. Disease-specific health disparities: a targeted review focusing on race and ethnicity. Healthcare (Basel). 2022;10:603.

Article  PubMed  Google Scholar 

Del Rincon I, Battafarano DF, Arroyo RA, Murphy FT, Fischbach M, Escalante A. Ethnic variation in the clinical manifestations of rheumatoid arthritis: role of HLA-DRB1 alleles. Arthritis Rheum. 2003;49:200–8.

Article  PubMed  Google Scholar 

Chinn JJ, Martin IK, Redmond N. Health equity among black women in the United States. J Womens Health (Larchmt). 2021;30:212–9.

Article  PubMed  Google Scholar 

Williams DR, Jackson PB. Social sources of racial disparities in health. Health Aff (Millwood). 2005;24:325–34.

Article  PubMed  Google Scholar 

Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care. 2009;47:350–5.

Article  PubMed  PubMed Central  Google Scholar 

Navarro-Millán I, Rajan M, Lui GE, et al. Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis. Semin Arthritis Rheum. 2020;50:988–95.

Article  PubMed  PubMed Central  Google Scholar 

Chopra A, Lin H-Y, Navarra SV, et al. Rheumatoid arthritis management in the APLAR region: perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseases. Int J Rheum Dis. 2021;24:1106–11.

Article  PubMed  Google Scholar 

Burgos-Vargas R, Catoggio LJ, Galarza-Maldonado C, Ostojich K, Cardiel MH. Current therapies in rheumatoid arthritis: a Latin American perspective. Reumatol Clin. 2013;9:106–12.

Article  PubMed  Google Scholar 

Zahir Hussain WH, Jubber A, Moorthy A. Are there any ethnic differences in the response to baricitinib for the treatment of rheumatoid arthritis? Cureus. 2021;13: e20024.

PubMed  PubMed Central  Google Scholar 

Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895–905.

Article  PubMed  CAS  Google Scholar 

Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970–81.

Article  PubMed  CAS  Google Scholar 

Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617–29.

Article  PubMed  CAS  Google Scholar 

Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63:1150–8.

Article  PubMed  CAS  Google Scholar 

Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015;25:514–21.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451–60.

Article  PubMed  CAS  Google Scholar 

van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–70.

Article  PubMed  Google Scholar 

Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.

Article  PubMed  CAS  Google Scholar 

Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253–61.

Article  PubMed  Google Scholar 

van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19.

Article  PubMed  Google Scholar 

Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–86.

Article  PubMed  Google Scholar 

Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457–68.

Article  PubMed  CAS  Google Scholar 

Radominski SC, Cardiel MH, Citera G, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: pooled efficacy and safety analyses of Phase 3 and long-term extension studies. Reumatol Clin. 2017;13:201–9.

Article  PubMed  Google Scholar 

Lee EB, Yamanaka H, Liu Y, et al. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: post-hoc analyses of pooled clinical study data. Int J Rheum Dis. 2019;22:1094–106.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Suarez-Almazor ME, Berrios-Rivera JP, Cox V, Janssen NM, Marcus DM, Sessoms S. Initiation of disease-modifying antirheumatic drug therapy in minority and disadvantaged patients with rheumatoid arthritis. J Rheumatol. 2007;34:2400–7.

PubMed  Google Scholar 

Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L. Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Rheum. 2009;61:413–8.

Article  PubMed  PubMed Central  Google Scholar 

Jordan MS, Lumley MA, Leisen JC. The relationships of cognitive coping and pain control beliefs to pain and adjustment among African-American and Caucasian women with rheumatoid arthritis. Arthritis Care Res. 1998;11:80–8.